FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1123-1124 October 12, 2000 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Dienstag, J. L. PubMed Citation

To the Editor: Lamivudine, a nucleoside analogue, has shown promising results in the treatment of hepatitis B virus (HBV) infection through its inhibitory action on reverse- transcriptase activity.^1,2 Lamivudine has been used to treat acute hepatitis B after liver transplantation and heart transplantation, and there are now preliminary results from a multicenter trial of its use after liver transplantation.^3,4 We report the use of lamivudine in a 74-year-old woman with acute hepatitis B.

The patient was admitted because of acute hepatitis B of two months' duration. Physical examination revealed a well-nourished, conscious woman with mild jaundice but otherwise normal findings. . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Dusheiko, G, Antonakopoulos, N (2008). Current treatment of hepatitis B. Gut 57: 105-124 [Full Text]  
• Perez-Roldan, F., Gonzalez-Carro, P., Villafanez-Garcia, M. C. (2005). Adefovir Dipivoxil for Chemotherapy-Induced Activation of Hepatitis B Virus Infection. NEJM 352: 310-311 [Full Text]  
• Gupta, S., Piraka, C., Jaffe, M. (2001). Lamivudine in the Treatment of Polyarteritis Nodosa Associated with Acute Hepatitis B. NEJM 344: 1645-1646 [Full Text]